Journal
CELLS
Volume 9, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cells9061405
Keywords
glioblastoma; oncolytic virotherapy; Newcastle disease virus (NDV); Interferon I
Categories
Funding
- Fondo de Investigaciones Sanitarias (FIS) [PI17-01489]
- Miguel Servet Program del Instituto de Salud Carlos III [CP11/00147]
- Ministerio de Economia y Competitividad-FEDERER [RTC-2016-4990-1]
- NIH [R01CA229818]
- Ayudas destinadas a la realizacion de doctorados industriales CAM [IND2019/BMD17222]
- FPI fellowship by Universidad San Pablo CEU
- Consejeria de Educacion e Investigacion de la Comunidad de Madrid [NIETO-CM B2017/BMD-3731]
- Proyectos Fundacion CEU-San Pablo Banco Santander Grant [PPC16/2015]
Ask authors/readers for more resources
Glioblastoma (GBM) is the most aggressive and frequent primary brain tumor in adults with a median overall survival of 15 months. Tumor recurrence and poor prognosis are related to cancer stem cells (CSCs), which drive resistance to therapies. A common characteristic in GBM isCDKN2Agene loss, located close to the cluster oftype I IFNgenes at Ch9p21. Newcastle disease virus (NDV) is an avian paramyxovirus with oncolytic and immunostimulatory properties that has been proposed for the treatment of GBM. We have analyzed theCDKN2A-IFN Igene cluster in 1018 glioma tumors and evaluated the NDV oncolytic effect in six GBM CSCs ex vivo and in a mouse model. Our results indicate that more than 50% of GBM patients have someIFNdeletion. Moreover, GBM susceptibility to NDV is dependent on the loss of thetype I IFN. Infection of GBM with an NDV-expressing influenza virus NS1 protein can overcome the resistance to oncolysis by NDV of type I-competent cells. These results highlight the potential of using NDV vectors in antitumor therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available